In a model of hepatocellular carcinoma, treatment with the histone deacetylase inhibitor, valproic acid (VPA), resulted in increased MICA and MICB cell-surface levels and simultaneous enhancement of their soluble forms in the conditioned media (72). This evidence concerns the gene MICA and hepatocellular carcinoma.